Korean com­pany launches anti-malaria drug in Kenya

BioSpectrum (Asia) - - World News -

Shin Poong Pharm in part­ner­ship with Per­spec­tive Health­care has launched a new Artemesinin Com­bi­na­tion Ther­apy (ACT) in the fight against Malaria. The drug has demon­strated high cure rates and pro­vides a long-term pro­tec­tion with less re­in­fec­tion. Pyra­max is a fixed-dose com­bi­na­tion of py­ronar­i­dine an­dartenusate and was co-de­vel­oped by Medicines for Malaria Ven­tures and Shin Poong Phar­ma­ceu­ti­cal Com­pany Limited of South Korea. Per­spec­tive Health­care are the Mar­ket­ing agents of the Pyra­max brand in East Africa while SurgiPharm are the lo­cal dis­tributers.

Pyra­max is the new­est ACT com­bi­na­tion to be ap­proved by a Strin­gent Reg­u­la­tory Author­ity and the only ACT to be granted a pos­i­tive sci­en­tific opin­ion un­der the Euro­pean Medicines Agency’s Ar­ti­cle 58 pro­ce­dure. Pyra­max is also the first South Korean prod­uct in­cluded in the World Health Or­gan­i­sa­tion’s (WHO) Model Lists of Es­sen­tial Medicines for adults and chil­dren. The drug has been taken through pre-clin­i­cal stud­ies and early clin­i­cal stud­ies lead­ing to four suc­cess­ful and im­por­tant Phase III clin­i­cal tri­als with more than 3,500 pa­tients in coun­tries in sub-Sa­ha­ran Africa, South East Asia and In­dia.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.